Distributed Transforms for Efficient Data Gathering in Sensor Networks

Devices, systems, and techniques for data collecting network such as wireless sensors are disclosed. A described technique includes detecting one or more remote nodes included in the wireless sensor network using a local power level that controls a radio range of the local node. The technique includes transmitting a local outdegree. The local outdegree can be based on a quantity of the one or more remote nodes. The technique includes receiving one or more remote outdegrees from the one or more remote nodes. The technique includes determining a local node type of the local node based on detecting a node type of the one or more remote nodes, using the one or more remote outdegrees, and using the local outdegree. The technique includes adjusting characteristics, including an energy usage characteristic and a data compression characteristic, of the wireless sensor network by selectively modifying the local power level and selectively changing the local node type

Next generation HTS system using hybrid satellite and terrestrial BB delivery- BATS

This paper presents the results from the EU FP 7 project BATS aimed at integrated BB access across the EU for 2020 and beyond. The BB access is integrated between DSL, LTE and the satellite and features a broadband intelligent user terminal. The satellite component is a cluster of two multibeam HTS satellites providing lower cost per bit than today’s satellites. The system architecture embedding the gateways and user terminals is presented as well as the design for the advanced satellites. The detailed design concepts of the intelligent router are also provided. We present the results of controlled lab tests on an emulated test bed as well as initial results from a field trial in which the intelligent routers were placed in households in Spain and Germany and connected to local; DSL and LTE as well as the Hylas satellite

Implementation of DVB-S2X super-frame format 4 for wideband transmission

Recently the extension of the digital video broadcasting second generation standard for transmission over satellite (DVB-S2) has been finalized in order to achieve a higher spectral efficiency without introducing fundamental changes to the complexity and structure of the common DVB-S2 standard. Therefore, this extension is termed DVB-S2X. In this paper, we focus on a more powerful physical layer frame structure, known as Super-Frame (SF), which has been adopted as optional waveform container in Annex E of the DVB-S2X specification. The paper provides insights to capabilities of the SF structure in support of emerging system applications.. Analytical results of the SF performance are complemented by the performance results obtained from an end-to-end testbed implementing SF format 4, which is optimized for wideband transmission and very low SNR reception conditions. The testbed includes prototype design of modulator and demodulator featuring the SF generation and detection capability. The prototype devices are able to operate at a wide range of signal-to-noise ratios and at high symbol rates. This design represents the basis for planned over-the-air tests using a single wideband satellite transponder to demonstrate the feasibility of transmitting and receiving 1 Gbit/s

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors demonstrated activity in terms of progression-free survival (PFS) in advanced dedifferentiated liposarcoma (DD-LPS), a sarcoma with CDK4 amplification. CDK4 overexpression is by far more common than amplification in sarcomas and it might be a rational target for CDK inhibitors. Preclinical investigators of this study found that CDK4 overexpression, while not of CDKN2A, was the most consistent predictive factor for palbociclib efficacy in sarcomas. Advanced adult-type soft-tissue sarcoma, excluding DD-LPS, or bone sarcoma patients, progressing after at least one systemic line, whose tumors overexpressed CDK4, but not CDKN2A at baseline biopsy, were accrued in this single-arm phase II trial (EudraCT number: 2016-004039-19). With the main endpoint of a 6-month PFS rate, 40% was considered promising in this population. Palbociclib was administered orally at 125 mg/day for 21 days in 28-day cycles. A total of 214 patients with 236 CDK4/CDKN2A determinations were assessed for prescreening, archival material (141), and screening, baseline biopsy (95). There were 28 (29%) with favorable mRNA profiles from 95 screened patients at baseline. From 23 enrolled patients, 21 evaluable, the 6-month PFS rate was 29% (95% CI 9-48), and there were 6 patients out of 21 with a PFS longer than 6 months. The median PFS and overall survival were 4.2 (95% CI 3.6-4.8) and 12 (95% CI 8.7-15.4) months, respectively. Translational research showed a significant correlation between CDK4 mRNA and protein expression. Palbociclib was active in a variety of sarcoma subtypes, selected by CDK4/CDKN2A, and deserves further investigation in the sarcoma context

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial

Background Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab).Methods This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level −1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II).Results From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4–26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3–4 adverse events included transaminitis (17.3%) and neutropenia (11.5%).Conclusions Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months.Trial registration number NCT03277924